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The tumor suppressor p53 plays a critical role in maintaining genomic
stability. In response to genotoxic stress, p53 levels increase and in-
duce cell-cycle arrest, senescence, or apoptosis, thereby preventing
replication of damaged DNA. In unstressed cells, p53 is maintained
at a low level. The major negative regulator of p53 is MDM2, an E3
ubiquitin ligase that directly interacts with p53 and promotes its
polyubiquitination, leading to the subsequent destruction of p53 by
the 26S proteasome. Following DNA damage, MDM2 is degraded
rapidly, resulting in increased p53 stability. Because of the important
role of MDM2 in modulating p53 function, it is critical to understand
how MDM2 levels are regulated. Here we show that the F-box
protein FBXO31, a candidate tumor suppressor encoded in 16q24.3
for which there is loss of heterozygosity in various solid tumors, is
responsible for promoting MDM2 degradation. Following genotoxic
stress, FBXO31 is phosphorylated by the DNA damage serine/
threonine kinase ATM, resulting in increased levels of FBXO31.
FBXO31 then interacts with and directs the degradation of MDM2,
which is dependent on phosphorylation of MDM2 by ATM. FBXO31-
mediated loss of MDM2 leads to elevated levels of p53, resulting in
growth arrest. In cells depleted of FBXO31, MDM2 is not degraded
and p53 levels do not increase following genotoxic stress. Thus,
FBXO31 is essential for the classic robust increase in p53 levels
following DNA damage.
p53 | MDM2 | FBXO31 | DNA damage | tumor suppressor
One of the most fundamental and extensively studied antican-cer mechanisms is the large increase in the levels of the tumor
suppressor p53 that occurs following DNA damage (reviewed in
ref. 1). The increased p53 then mediates growth arrest and/or ap-
optosis. The importance of this anticancer mechanism is highlighted
by the mutation or functional inactivation of the p53 gene in more
than 50% of human cancers (2, 3).
In unstressed cells, p53 is maintained at a low level. The major
negative regulator of p53 is MDM2, an E3 ubiquitin ligase that
interacts directly with p53 and promotes its polyubiquitination,
leading to the subsequent destruction of p53 by the 26S proteasome
(reviewed in ref. 4). Following DNA damage, MDM2 is degraded
rapidly, resulting in increased p53 stability. Originally it was pro-
posed that MDM2 degradation was caused by auto-ubiquitination;
however, subsequent experiments showed that the E3 ubiquitin li-
gase activity of MDM2 is not required for its degradation (5).
We originally identified the F-box protein FBXO31 in an RNAi
screen as one of 17 factors required for oncogenic BRAF to in-
duce senescence in primary human cells (6). F-box proteins are
best known for their role as the substrate-recognition components
of the SKP1/CUL1/F-box protein (SCF) class of E3 ubiquitin li-
gases (7). The F-box motif is responsible for the ability of F-box
proteins to interact with the SCF complex and to promote ubiq-
uitination of their targets (8).
One of the other genes we isolated in our original RNAi screen
was p53 (6), raising the possibility that FBXO31 and p53 function in
a common pathway(s). Consistent with this idea, both FBXO31 and
p53 can induce growth arrest (9, 10), and we have found that after
DNA damage there is a posttranslational increase of FBXO31
levels, as there is for p53 (9). These considerations prompted us to
ask whether there was a functional relationship between FBXO31
and p53.
Results
FBXO31 Is Required for Decreased MDM2 and Increased p53 Levels
Following DNA Damage. We asked whether the ability of FBXO31
to induce growth arrest results, at least in part, from the regulation
of p53 levels. Toward this end, p53-positive MCF7 cells expressing
either a control nonsilencing (NS) shRNA or an FBXO31 shRNA
were treated with the DNA-damaging agent camptothecin or
γ-irradiation, and the levels of p53 and MDM2 were analyzed by
immunoblotting. Previous studies have shown that MDM2 levels
decrease rapidly following genotoxic stress (4), and therefore in
the first set of experiments we monitored the levels of p53 and
other proteins at early times after the induction of DNA damage.
Within 90 min following camptothecin (Fig. 1A) or γ-irradiation
(Fig. 1B) treatment of MCF7 cells expressing a control NS shRNA,
FBXO31 levels increased, as was consistent with previous results
from our laboratory (9) and others (11). This increase in FBXO31
levels was accompanied by decreased MDM2 levels and increased
p53 levels, as expected. Following camptothecin or γ-irradiation
treatment of FBXO31 knockdown (KD) cells, there was a marked
reduction in FBXO31 levels, as expected, but, notably, MDM2
and p53 levels remained constant. Similar results were obtained
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in p53-positive IMR90 cells (Fig. S1 A and B) and using a sec-
ond, unrelated FBXO31 shRNA (Fig. S1 C–E).
A previous study suggested that following DNA damage the
apparent decrease in MDM2 levels as monitored by immunoblot-
ting in actuality is caused not by MDM2 degradation but rather by a
conformational change in MDM2 that results in the masking of
epitopes recognized by monoclonal anti-MDM2 antibodies (12)
such as the AB1 antibody used in the experiments shown in Fig. 1 A
and B and Fig. S1 A and B. Although this conclusion has been
challenged by other studies (13), we performed two additional ex-
periments to confirm that MDM2 is truly degraded following DNA
damage in control but not in FBXO31 KD cells. First, in the ex-
periments described above, MDM2 levels also were monitored using
a polyclonal anti-MDM2 antibody (N20). Similar to the results with
the AB1 monoclonal anti-MDM2 antibody, we found that after
DNA damage MDM2 levels decreased in cells expressing the con-
trol NS shRNA but not in FBXO31 KD cells (Fig. 1 A and B and
Fig. S1 A and B). Second, we ectopically expressed an N-terminal
Flag-tagged MDM2 in control or FBXO31 KD MCF7 cells and,
after DNA damage, monitored MDM2 levels using an anti-Flag
antibody. The immunoblot results of Fig. 1C show that after
camptothecin treatment in control MCF7 cells, the levels of ectop-
ically expressed Flag-MDM2 decreased, and this decrease was ac-
companied by increased levels of endogenous p53. In contrast, after
camptothecin treatment in FBXO31 KD cells, the levels of ectop-
ically expressed Flag-MDM2 and endogenous p53 were un-
affected.
The finding that in FBXO31 KD cells p53 levels failed to in-
crease following DNA damage suggested that growth arrest would
not occur efficiently. To test this prediction, we measured the mi-
totic index of control and FBXO31 KD cells in the presence of
nocodazole to trap cells in mitosis. After DNA damage, cells har-
boring p53 arrest in G2 and G1, whereas cells lacking p53 will pro-
gress through the cell cycle and enter mitosis (14).
These experiments were performed in p53-positive HCT116
cells, which previously have been shown to undergo p53-dependent
growth arrest in a mitotic index assay (14). Similar to the other
p53-positive cell lines analyzed above, in FBXO31 KD HCT116
cells, MDM2 levels did not decrease and p53 levels did not in-
crease after DNA damage (Fig. S1F). The results shown in
Fig. 1D demonstrate that at 18 and 24 h following γ-irradiation the
mitotic index of FBXO31 KD HCT116 cells was markedly higher
than that of control HCT116 cells expressing an NS shRNA. No-
tably, the difference in mitotic index between control and FBXO31
KD HCT116 cells correlated with levels of p53 and the p53 target
p21 (Fig. S1G), which plays a critical role in p53-mediated growth
arrest (15, 16).
FBXO31 Directs Degradation of MDM2. The results described above
suggested that FBXO31 directly mediates degradation of MDM2,
and we performed a series of experiments to confirm this possibility.
First, we measured the half-life of endogenous MDM2 using a
cycloheximide-chase/immunoblot assay. The results show that the
half-life of MDM2 was substantially longer in FBXO31 KD MCF7
cells than in control cells (Fig. 2A and Fig. S2 A and B). Similar re-
sults were obtained in IMR90 cells (Fig. S2C).
We next asked whether ectopic expression of FBXO31 would
result in the degradation of endogenous MDM2. As was consistent
with previous results (17), we found that ectopic expression of
FBXO31 in MCF7 cells promoted growth arrest, as evidenced by
reduced proliferation (Fig. S3A) and decreased DNA replication
(BrdU incorporation) (Fig. S3B), and induced senescence, as evi-
denced by positive staining for senescence-associated β-gal (Fig.
S3C). The immunoblot of Fig. 2B shows that ectopic expression
of FBXO31 resulted in decreased levels of MDM2, which, as ex-
pected, were accompanied by increased levels of p53 and p21.
Notably, previous studies have shown that increased p21 levels
are sufficient to induce growth arrest and senescence (18, 19). In
contrast to wild-type FBXO31, ectopic expression of an FBXO31
derivative in which the F-box had been deleted (FBXO31ΔF) (17)
failed to result in decreased levels of MDM2 or increased levels
of p53 and p21.
Consistent with our finding that FBXO31 affected MDM2 sta-
bility, the addition of the proteasome inhibitor lactacystin blocked
the ability of ectopically expressed FBXO31 to decrease MDM2
levels (Fig. 2C). In addition, quantitative RT-PCR (qRT-PCR)
analysis showed that MDM2 mRNA levels were unaffected by ec-
topic FBXO31 expression or after FBXO31 knockdown (Fig. S4A).
Moreover, ectopic expression of FBXO31, but not FBXO31ΔF,
substantially reduced the half-life of MDM2 in MCF7 cells (Fig. 2D
and Fig. S4B) and in 293T cells (Fig. S4C).
Finally, to confirm the antagonistic roles of MDM2 and FBXO31
on p53 levels, we performed reconstitution experiments in homo-
zygous knockout mouse embryo fibroblasts (MEFs) lacking MDM2
and p53 (Mdm2−/−, p53−/− MEFs). We ectopically expressed GFP-
p53 alone, GFP-p53 and Flag-MDM2, or GFP-p53, Flag-MDM2,
and myc-FBXO31 and measured p53 protein levels by immuno-
blotting. The results in Fig. 2E show, as expected, a reduction in p53
levels in the presence of MDM2. Notably, expression of FBXO31
led to decreased levels of MDM2 and a restoration of p53 levels. To
confirm that these effects resulted from alterations of protein sta-
bility, the half-lives of p53 and MDM2 were measured by a cyclo-
heximide-chase/immunoblot assay. The results in Fig. 2F show that
the half-life of p53 was markedly reduced in the presence of MDM2
and that expression of FBXO31 led to a large decrease in the
Fig. 1. FBXO31 is required for decreased MDM2 and increased p53 levels following DNA damage. (A and B) Immunoblot monitoring MDM2 [using a
monoclonal (AB1) or polyclonal (N20) antibody], p53, FBXO31, phosphorylated ATM [p-ATM(1981)], and total ATM (t-ATM) in MCF7 cells expressing NS or
FBXO31 shRNA and treated in the presence (45 or 90 min) or absence (0 min) of camptothecin (A) or γ-irradiation (IR) (B). α-tubulin (TUBA) was monitored as
loading control. (C) Immunoblot monitoring Flag-MDM2, p53, and FBXO31 in MCF7 cells expressing Flag-MDM2 and NS or FBXO31 shRNA and treated in the
presence or absence of camptothecin. GFP, expressed from a cotransfected plasmid, was used as a transfection and loading control. (D) Mitotic index analysis
of HCT116 cells expressing NS or FBXO31 shRNA. Error bars indicate SD. *P ≤ 0.05, **P ≤ 0.01.
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half-life of MDM2 and a concomitant increase in the half-life of p53
(see also Fig. S4D).
FBXO31 Interacts Directly with MDM2. F-box proteins impart sub-
strate specificity to the SCF ubiquitin ligase machinery by interacting
directly with their protein targets (8). To test whether FBXO31 and
MDM2 interact, we performed a series of coimmunoprecipitation
experiments. First, MCF7 cells were stably transduced with a ret-
rovirus expressing myc-tagged FBXO31, and FBXO31 was immu-
noprecipitated using an anti-myc antibody. Fig. 3A shows the
presence of MDM2 in the FBXO31 immunoprecipitate, which was
increased by lactacystin addition. The reciprocal coimmunopreci-
pitation experiment showed the presence of myc-FBXO31 in the
MDM2 immunoprecipitate.
The FBXO31–MDM2 Interaction Is Dependent on Phosphorylation of
MDM2 by ATM. Recognition by F-box proteins typically requires
phosphorylation of the substrate, which serves as a signal for
ubiquitin-dependent destruction (8). Fig. 3B shows that the
FBXO31–MDM2 interaction was lost, as expected, after treat-
ment of cell extracts with λ-phosphatase, which nonspecifically
removes phosphoryl groups.
MDM2 is phosphorylated by several protein kinases in-
cluding the DNA damage response-initiating kinase ATM (20,
21), AKT (22, 23), cyclin-dependent kinases (CDKs) (24), ca-
sein kinase 1 (CK1) (25), and mammalian target of rapamycin/
S6K1 (mTOR) (26). We analyzed the effect of chemical in-
hibitors of these kinases on MDM2 levels in MCF7 cells after ec-
topic expression of FBXO31. Fig. 3C shows that treatment of cells
with the two different ATM inhibitors, KU-55933 (27) and caffeine
(28), resulted in a substantial increase in the levels of
MDM2, indicating decreased FBXO31-directed degradation. In
contrast, treatment of cells with inhibitors of the PI3K/AKT
pathway, i.e., LY294002 (29), CDKs [CR8 (30)], CK1 [D4476
(31)], or mTOR [rapamycin (32)], had either no or only a modest
effect on MDM2 levels. Consistent with the results of a previous
study (25), treatment with the CK1 inhibitor D4476 also in-
creased MDM2 levels, but the effect was much less than that
observed following ATM inhibition.
We have shown previously that FBXO31 itself is phosphorylated
by ATM (9). Therefore, it remained possible that the loss of the
FBXO31–MDM2 interaction following ATM inhibition was caused,
at least in part, by a failure to phosphorylate FBXO31. To rule out
this possibility, we analyzed an FBXO31 derivative containing a mu-
tation within the ATM phosphorylation site that prevents phos-
phorylation (FBXO31-SDM1) (9). Fig. 3D shows that wild-type
FBXO31 and the FBXO31-SDM1 mutant interacted with MDM2
comparably.
Finally, we analyzed an MDM2 derivative in which all six ATM
phosphorylation sites were mutated (MDM2-6A) (33). A plasmid
expressing wild-type MDM2 or MDM2-6A was cotransfected with
an FBXO31 expression plasmid into Mdm2−/−, p53−/− MEFs, and
MDM2 levels were monitored by immunoblotting. As shown in
Fig. 3E, FBXO31 failed to reduce MDM2-6A levels, confirming the
essential role of ATM in FBXO31-directed degradation of MDM2.
The experiments described above were performed with ectopi-
cally expressed FBXO31 and/or MDM2. We next performed
coimmunoprecipitation experiments in camptothecin-treated
MCF7 cells to detect an interaction between endogenous FBXO31
and MDM2. The coimmunoprecipitation experiment in Fig. 3F
shows that an interaction could be detected between endogenous
FBXO31 and MDM2. The FBXO31–MDM2 interaction was lost
following treatment of cell extracts with λ-phosphatase but was
restored upon the addition of phosphatase inhibitors. Also, as is
consistent with the results described above, Fig. 3G shows that the
interaction between endogenous FBXO31 and MDM2 was lost
following treatment of MCF7 cells with the ATM inhibitor
KU-55933. Finally, the coimmunoprecipitation experiment in Fig.
S5 shows that an ATM-dependent interaction between endoge-
nous FBXO31 and MDM2 also could be detected in IMR90 cells.
FBXO31 Directs Polyubiquitination of MDM2. Typically, F-box pro-
teins direct polyubiquitination of their substrates, resulting in
proteasome-mediated degradation (7, 34). We performed a series
of experiments to determine whether FBXO31 can direct poly-
ubiquitination of MDM2. In these experiments, cells were treated
with the proteasome inhibitor MG132 to minimize degradation of
polyubiquitinated proteins. In the first experiment, MCF7 cells
Fig. 2. FBXO31 directs degradation of MDM2. (A) Quantification of a cycloheximide-chase/immunoblot assay monitoring MDM2 stability in MCF7 cells
expressing NS or FBXO31 shRNA following treatment with cycloheximide. The graph shows the ratio of the relative levels of MDM2 and PCNA (control) at
each time point; time 0 was set to 100%. (B) Immunoblot monitoring MDM2, p53, and p21 in MCF7 cells expressing empty vector, FBXO31, or FBXO31ΔF.
(C) Immunoblot monitoring MDM2 in MCF7 cells expressing vector or FBXO31 and treated in the presence or absence of lactacystin. (D) Quantification of a
cycloheximide-chase/immunoblot assay monitoring Flag-MDM2 stability in cycloheximide-treated MCF7 cells expressing GFP (control), FBXO31, or FBXO31ΔF.
(E) Immunoblot monitoring GFP-p53, Flag-MDM2, and myc-FBXO31 inMdm2−/−, p53−/−MEFs coexpressing combinations of p53, MDM2, and FBXO31. β-Actin
(ACTB) was monitored as a loading control. (F) Quantification of a cycloheximide-chase/immunoblot assay monitoring GFP-p53 and Flag-MDM2 stability in
cycloheximide-treated Mdm2−/−, p53−/− MEFs coexpressing combinations of p53, MDM2, and FBXO31.
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were cotransfected with plasmids expressing Flag-MDM2, HA-tag-
ged ubiquitin, and either myc-FBXO31 or myc-FBXO31ΔF. Poly-
ubiquitination of MDM2 was assessed by immunoprecipitation of
Flag-MDM2 followed by immunoblotting for HA-ubiquitin. The re-
sults of Fig. 4A show that ectopic expression of FBXO31, but not
FBXO31ΔF, resulted in polyubiquitination of MDM2. Similar re-
sults were obtained in a reciprocal coimmunoprecipitation experiment.
Notably, FBXO31-directed polyubiquitination of MDM2 was lost af-
ter treatment of cells with the ATM inhibitor KU-55933 (Fig. S6A).
To confirm these results, we performed another in vivo ubiq-
uitination experiment involving cotransfection of plasmids express-
ing Flag-MDM2, His-tagged ubiquitin, and either myc-FBXO31 or
myc-FBXO31ΔF. His-ubiquitin–conjugated proteins were purified
under stringent, denaturing conditions, followed by immunoblotting
for Flag-MDM2. The results confirm that ectopic expression of
FBXO31, but not FBXO31ΔF, resulted in polyubiquitination of
MDM2 (Fig. S6B).
We also used this His-ubiquitin pull-down assay to confirm
the antagonistic relationship of MDM2 and FBXO31 on poly-
ubiquitination of p53. In p53-negative H1299 cells we ectopically
expressed His-ubiquitin with GFP-p53 alone, GFP-p53 and
Flag-MDM2, or GFP-p53, Flag-MDM2, and myc-FBXO31.
Polyubiquitinated p53 was detected by purifying His-ubiquitin–
conjugated proteins followed by immunoblotting for GFP-p53.
The results show that ectopic expression of MDM2 resulted in
a substantial increase in polyubiquitination of p53, which was
counteracted by the coexpression of FBXO31 (Fig. S6C).
The ubiquitination assays described above were performed with
ectopically expressed proteins. We next performed an additional
in vivo ubiquitination experiment to confirm that endogenous
FBXO31 could polyubiquitinate endogenous MDM2. Extracts from
untreated or camptothecin-treated MCF7 cells expressing either an
NS or FBXO31 shRNA were immunoprecipitated with an anti-
MDM2 antibody, and the immunoprecipitate was analyzed by im-
munoblotting with an anti-ubiquitin antibody. As expected, the results
of Fig. 4B show that camptothecin treatment led to a large increase in
polyubiquitinated MDM2. Notably, knockdown of FBXO31 sub-
stantially reduced the amount of polyubiquitinated MDM2 in
camptothecin-treated cells. These results indicate that FBXO31 is
required for polyubiquitination of MDM2 following DNA damage.
Finally, we performed an in vitro ubiquitination assay. Previous
studies have shown that MDM2 has auto-ubiquitinating activity in
vitro in the presence of an E1 ubiquitin-activating enzyme and E2
ubiquitin-conjugating enzyme (35, 36). Therefore, we used a pre-
viously described catalytically inactive MDM2 mutant, MDM2
(C464A) (35). In addition to MDM2(C464A), the reaction mixtures
contained or lacked the known cofactors (E1, E2, ubiquitin, and
ATP), ATM, and the SCF/myc-FBXO31 complex purified from
transfected 293T cells. The results in Fig. 4C show that in vitro
polyubiquitination ofMDM2(C464A) was dependent on the addition
of the known cofactors, ATM, and the myc- SCF/FBXO31 complex.
Discussion
In this report we show an essential role for FBXO31 in MDM2
degradation following genotoxic stress that is summarized in the
schematic model shown in Fig. 4D and discussed below. Following
DNA damage, FBXO31 is phosphorylated by ATM, resulting in
increased levels of FBXO31. FBXO31, as part of the SCF complex,
then interacts directly with and mediates the degradation of
MDM2, which is dependent on the phosphorylation of MDM2 by
Fig. 3. FBXO31 interacts with MDM2 directly in a manner that is dependent on phosphorylation of MDM2 by ATM. (A) Coimmunoprecipitation monitoring
the interaction between ectopically expressed FBXO31 and endogenous MDM2 in MCF7 cells expressing vector or myc-FBXO31 and treated in the presence or
absence of lactacystin. IP, immunoprecipitation. (B) Coimmunoprecipitation monitoring the FBXO31–MDM2 interaction in MCF7 cells treated in the pres-
ence or absence of λ-phosphatase. (C) Immunoblot monitoring MDM2 in MCF7 cells ectopically expressing FBXO31 and treated with kinase inhibitors.
(D) Coimmunoprecipitation monitoring the FBXO31–MDM2 interaction in MCF7 cells expressing vector, myc-FBXO31, or myc-FBXO31-SDM1. (E) Immunoblot
monitoring MDM2 inMdm2−/−, p53−/−MEFs expressing vector or myc-FBXO31 and wild-type MDM2 or MDM2-6A. (F) Coimmunoprecipitation monitoring the
endogenous FBXO31–MDM2 interaction in camptothecin-treated MCF7 cells in the presence or absence of λ-phosphatase or NaF/Na3VO4. (G) Coimmuno-
precipitation monitoring the endogenous FBXO31–MDM2 interaction in MCF7 cells treated in the presence or absence of camptothecin or KU-55933.
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ATM. The decreased MDM2 results in increased levels of p53,
which promotes growth arrest and senescence through transcrip-
tional activation of p21 and other p53 target genes. Thus, FBXO31
is essential for the classic robust increase in p53 levels following
DNA damage.
We have shown previously that in p53-deficient SK-MEL-28
cells FBXO31 also can induce G1 arrest following DNA damage
through interaction with and degradation of cyclin D1 (9). Thus,
following genotoxic stress, FBXO31 can induce growth arrest through
two independent pathways that differ with regard to both substrates
and p53 dependence.
Previous studies have shown that in response to DNA damage,
MDM2 degradation also is mediated by the F-box protein beta-
transducin repeat containing E3 ubiquitin ligase protein (b-TRCP;
also called BTRC) and requires phosphorylation of MDM2 by
CKIδ (25). Although our results do not rule out the possibility that
β-TRCP contributes to MDM2 degradation, FBXO31 appears to
have the predominant role, at least in the cell types we analyzed
(see, for example, Fig. 3C).
ATM is considered the main transducer of the DNA damage
response that is activated by double-strand breaks (37). Therefore
it is notable that after DNA damage ATM phosphorylates both
FBXO31, leading to its stabilization, and MDM2, enabling in-
teraction with and degradation by FBXO31. Collectively, the re-
sults presented here highlight the critical function of FBXO31 in
the DNA damage response and provide further support for the
role of FBXO31 as a tumor suppressor.
Materials and Methods
DNA replication and senescence assays are described in SI Materials and
Methods.
Cell Lines and Culture.MCF7, IMR90, H1299, and 293T cells were obtained from
ATCC and were grown as recommended. Cell lines stably expressing empty
vector, myc-FBXO31, or myc-FBXO31ΔF were generated by retroviral trans-
duction as described (9). Cells were treated with camptothecin (20 μM; Sigma)
or γ-irradiation (20 Gy) for 45 or 90 min, MG132 (10 μM; Sigma) for 4 h, lac-
tacystin (5 μM; Calbiochem) for 8 h; or KU-55933 (10 μM; Tocris Bioscience),
caffeine (1 mM; Sigma), LY294002 (10 μM; Cayman Chemical), CR8 (10 μM;
Tocris Bioscience), D4476 (1 μM; Cayman), or rapamycin (5 μM; Calbiochem) for
24 h. FBXO31 KD cells were generated using lentiviral shRNAs (FBXO31-1,
TGCTGTTGACAGTGAGCGAGCAAAGGTTCCTAAATGGTAATAGTGAAGCCACA-
GATGTATTACCATTTAGGAACCTTTGCCTGCCTACTGCCTCGGA and FBXO31-2,
TGCTGTTGACAGTGAGCGAGCAAAGGTTCCTAAATGGTAATAGTGAAGCCACA-
GATGTATTACATTTAGGAACCTTTGCCTGCCTACGCCTCGGA; Open Biosystems/
GE Dharmacon) as described (9). Mdm2−/−, p53−/− MEFS (provided by Stephen
Jones, University of Massachusetts Medical School, Worcester, MA) were trans-
fected with pCMV-MDM2-WT and pCMV-MDM2-6A plasmids (provided by
Jiandong Chen, Moffitt Cancer Center, Tampa, FL). HCT116 cells (14) were pro-
vided by B. Vogelstein of Johns Hopkins University, Baltimore, and were grown
in RPMI1640 medium containing 10% (vol/vol) FBS.
Immunoblotting. Protein extracts were prepared and immunoblotting was
performed as described (9) using the following antibodies: mouse monoclonal
MDM2 (AB1; Calbiochem), rabbit polyclonal MDM2 (N20; Santa Cruz), mouse
monoclonal p53 (DO1; Santa Cruz), FBXO31 (Bethyl Laboratories, Inc.), phos-
pho-ATM Ser1981 (Cell Signaling), ATM (Cell Signaling), p21 (Cell Signaling),
myc (Roche), Flag (Sigma), GFP (Santa Cruz), Proliferating cell nuclear antigen
(PCNA; (Santa Cruz), 6×-His (Abcam), β-actin (Sigma), and α-tubulin (Sigma).
Mitotic Index. HCT116 cells were seeded on a coverslip (5 × 104 cells per 12-well
plate) and were exposed on the following day to 10-Gy ionizing radiation
(Cobalt-60 irradiator). Thirty minutes later, nocodazole (200 nM; Sigma) was
added to the cells for 18 or 24 h, or, as a control, cells were left untreated
(0 h time point). Cells then were collected, fixed with 3.7% (vol/vol) formal-
dehyde in PBS for 30 min at 37 °C, and washed three times in PBS. When all
time points were collected, cells were permeabilized with chilled methanol,
stained with Hoechst 33258 (10 mg/mL) in PBS, and washed three times in PBS.
Nuclei were visualized by fluorescence microscopy (Olympus). Nuclei with
condensed, evenly staining chromosomes were scored as mitotic. At least 200
cells were counted for each sample.
Cycloheximide Chase. For the experiments monitoring endogenous MDM2,
MCF7 or IMR90 cells were infectedwith a lentivirus expressing anNS or FBXO31
shRNA and puromycin selected for 5 d. Cells then were treated with cyclo-
heximide (100 μg/mL; Sigma). For the experiments monitoring Flag-MDM2,
MCF7 cells or 293T cells were cotransfected with a plasmid expressing Flag-
MDM2 (provided by Ze’ev Ronai, Sanford-BurnhamMedical Research Institute,
La Jolla, CA) and a plasmid expressing GFP (pEGFPC1; Clontech), myc-FBXO31,
or myc-FBXO31ΔF. Thirty hours later, cells were treated with cycloheximide
Fig. 4. FBXO31 directs polyubiquitination of MDM2.
(A) In vivo assay monitoring ubiquitination of Flag-
MDM2 in MCF7 cells expressing Flag-MDM2, HA-ubiq-
uitin, and either myc-FBXO31 or myc-FBXO31ΔF. GFP
expressed from a cotransfected plasmid was used as
transfection/loading control. (B) In vivo assay monitoring
the ubiquitination of endogenous MDM2 in MCF7 cells
expressing NS or FBXO31 shRNA and treated in the
presence or absence of camptothecin. (C) In vitro ubiq-
uitination assay monitoring the ability of a purified
FBXO31/CUL1/SKP1/ROC1 complex to ubiquitinate GST-
MDM2(C464A). (D) Model. Ub, ubiquitin.
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(100 μg/mL). For experiments in Mdm2−/−, p53−/− MEFS, cells were transfected
with plasmids expressing GFP-p53 (Addgene), Flag-MDM2, and myc-FBXO31 in
various combinations, and 30 h later, cells were treated with cycloheximide
(50 μg/mL). Total cell extracts were prepared as described above and subjected
to immunoblotting with Flag (Sigma), myc (Roche), GFP (FL Santa Cruz), and
PCNA (Cell Signaling) antibodies. Band intensities were quantified using Image J
software version 1.47v (NIH).
qRT–PCR. Total RNA was isolated and reverse transcription was performed as
described (9), followed by qRT-PCR using MDM2 forward (5′-CATTGTCCATGG-
CAAAACAG-3′) and reverse (5′-GGCAGGGCTTATTCCTTTTC-3′) primers.
Coimmunoprecipitation. Coimmunoprecipitation assays were performed as de-
scribed (9). Lactacystin (5 μM; Calbiochem) was added for 8 h before preparation
of the protein extract. For λ-phosphatase treatment (Fig. 3F), whole-cell extract
prepared from MCF7 cells treated with camptothecin (20 μM for 45 min) was
either mock treated or treated with λ-phosphatase (2,000 U) for 30 min at 30 °C
in the presence or absence of 10 mM NaF (Sigma) and 1 mM Na3VO4 (Sigma).
FBXO31 coimmunoprecipitations were performed using a previously described
polyclonal antibody (9). Blots were probed with the antibodies described above,
including Cullin 1 (CUL1; Cell Signaling). For the assays shown in Fig. 3G and
Fig. S5, cells were treated with KU-55933 for 12 h before extract preparation.
Ubiquitination Assays. For in vivo assays, MCF7 cells were cotransfected with
plasmids expressing Flag-MDM2, HA-tagged ubiquitin (Addgene), and either myc-
FBXO31 or myc-FBXO31ΔF; 36 h later, cells were treated with 10 μM MG132 for
4 h andwere lysed in cell lysis buffer containing 10mMN-ethylmaleimide (Sigma).
For the His-ubiquitin pull-down assays, H1299 cells were transfected with plasmids
expressing His-ubiquitin (Addgene), Flag-MDM2, myc-FBXO31, myc-FBXO31ΔF,
and either GFP alone or GFP-p53 in various combinations. Thirty hours post-
transfection, cells were treated with MG132 (20 μm for 4 h) and then were har-
vested and used for purification of His6-tagged proteins by Ni-NTA beads. The cell
pellet was lysed in buffer A [6 M guanidinium·HCl, 0.1 M Na2HPO4/NaH2PO4,
0.01M Tris·Cl (pH 8.0), 5 mM imidazole, 10 mM β-mercaptoethanol] and incubated
with Ni-NTA beads (Qiagen) for 4 h at room temperature. The beads were
washed with buffers A, B [8 M urea, 0.1 M Na2PO4/NaH2PO4, 0.01 M Tris·Cl
(pH 8.0), 10 mM β-mercaptoethanol], and C [8 M urea, 0.1 M Na2PO4/
NaH2PO4, 0.01 M Tris·Cl (pH 6.3), 10 mM β-mercaptoethanol], and bound proteins
were eluted with buffer D [200 mM imidazole, 0.15 M Tris·Cl (pH 6.7), 30% (vol/
vol) glycerol, 0.72 M β-mercaptoethanol, 5% (wt/vol) SDS]. The eluted proteins
were analyzed by immunoblotting.
For the in vivo assay, extracts from MCF7 cells were treated with DMSO or
camptothecin (25 μM for 45 min) and MG132 (10 μM for 6 h) before
immunoprecipitation.
The in vitro ubiquitination assay was performed as described (9). Briefly,
293T cells were cotransfected with plasmids encoding myc-CUL1, myc-SKP1,
myc-ROC1, and myc-FBXO31. Complexes containing FBXO31/CUL1/SKP1/ROC
were immunopurified from the cell lysate using anti-myc beads and were
incubated with recombinant GST-MDM2(C464A) (provided by Allan Weiss-
man, National Cancer Institute, Bethesda), purified recombinant active ATM
(provided by Tanya Paull, University of Texas at Austin, Austin, TX), 0.1 mm
E1 (Boston Biochem), 0.25 mm E2 (UBCH5A; Boston Biochem), and 2.5 μg/mL
ubiquitin (Boston Biochem) in ubiquitin assay buffer [10 mM Tris (pH 7.5),
100 mM NaCl, 2.5 mMMgCl2, 2.5 mM ATP, 1 mM DTT, and 10 mMMnCl2] for
2 h at 30 °C, and were analyzed by immunoblotting.
Statistical Analysis. All quantitative data were collected from experiments per-
formed in at least triplicate and are expressed asmean± SD. Differences between
groups were assayed using two-tailed Student t test using Microsoft Excel.
ACKNOWLEDGMENTS. We thank Jiandong Chen, Stephen Jones, Tanya Paull,
Ze’ev Ronai, Allan Weissman, and Bert Vogelstein for providing reagents and
Sara Deibler for editorial assistance. This work was supported in part by a
Ramalingaswami Fellowship from the Department of Biotechnology, Ministry
of Science and Technology, Government of India (to M.K.S.). M.R.G. is an in-
vestigator of the Howard Hughes Medical Institute.
1. Kumari R, Kohli S, Das S (2014) p53 regulation upon genotoxic stress: Intricacies and
complexities. Mol Cell Oncol 1(3):e969653.
2. Petitjean A, et al. (2007) Impact of mutant p53 functional properties on TP53 muta-
tion patterns and tumor phenotype: Lessons from recent developments in the IARC
TP53 database. Hum Mutat 28(6):622–629.
3. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310.
4. Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer
therapy. Nat Rev Cancer 13(2):83–96.
5. Itahana K, et al. (2007) Targeted inactivation ofMdm2RING finger E3 ubiquitin ligase activity
in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12(4):355–366.
6. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF
induces senescence and apoptosis through pathways mediated by the secreted pro-
tein IGFBP7. Cell 132(3):363–374.
7. Skaar JR, Pagan JK, Pagano M (2013) Mechanisms and function of substrate re-
cruitment by F-box proteins. Nat Rev Mol Cell Biol 14(6):369–381.
8. Ho MS, Tsai PI, Chien CT (2006) F-box proteins: The key to protein degradation.
J Biomed Sci 13(2):181–191.
9. Santra MK, Wajapeyee N, Green MR (2009) F-box protein FBXO31 mediates cyclin D1
degradation to induce G1 arrest after DNA damage. Nature 459(7247):722–725.
10. Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb
Perspect Biol 1(5):a001883.
11. Liu J, et al. (2014) F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-
activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitina-
tion and degradation of mitogen-activated protein kinase kinase 6 (MKK6). J Biol
Chem 289(31):21508–21518.
12. Cheng Q, Chen J (2010) Mechanism of p53 stabilization by ATM after DNA damage.
Cell Cycle 9(3):472–478.
13. Wang Z, et al. (2012) DNA damage-induced activation of ATM promotes β-TRCP-
mediated Mdm2 ubiquitination and destruction. Oncotarget 3(9):1026–1035.
14. Bunz F, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA
damage. Science 282(5393):1497–1501.
15. el-Deiry WS, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell
75(4):817–825.
16. Waldman T, Kinzler KW, Vogelstein B (1995) p21 is necessary for the p53-mediated G1
arrest in human cancer cells. Cancer Res 55(22):5187–5190.
17. Kumar R, et al. (2005) FBXO31 is the chromosome 16q24.3 senescence gene, a can-
didate breast tumor suppressor, and a component of an SCF complex. Cancer Res
65(24):11304–11313.
18. Fang L, et al. (1999) p21Waf1/Cip1/Sdi1 induces permanent growth arrest with
markers of replicative senescence in human tumor cells lacking functional p53. On-
cogene 18(18):2789–2797.
19. Wang Y, Blandino G, Givol D (1999) Induced p21waf expression in H1299 cell line
promotes cell senescence and protects against cytotoxic effect of radiation and
doxorubicin. Oncogene 18(16):2643–2649.
20. Khosravi R, et al. (1999) Rapid ATM-dependent phosphorylation of MDM2 precedes p53
accumulation in response to DNA damage. Proc Natl Acad Sci USA 96(26):14973–14977.
21. Maya R, et al. (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: Role
in p53 activation by DNA damage. Genes Dev 15(9):1067–1077.
22. Ogawara Y, et al. (2002) Akt enhances Mdm2-mediated ubiquitination and degra-
dation of p53. J Biol Chem 277(24):21843–21850.
23. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes
translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA
98(20):11598–11603.
24. Zhang T, Prives C (2001) Cyclin a-CDK phosphorylation regulates MDM2 protein in-
teractions. J Biol Chem 276(32):29702–29710.
25. Inuzuka H, et al. (2010) Phosphorylation by casein kinase I promotes the turnover of the
Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 18(2):147–159.
26. Lai KP, et al. (2010) S6K1 is a multifaceted regulator of Mdm2 that connects nutrient
status and DNA damage response. EMBO J 29(17):2994–3006.
27. Hickson I, et al. (2004) Identification and characterization of a novel and specific in-
hibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64(24):
9152–9159.
28. Blasina A, Price BD, Turenne GA, McGowan CH (1999) Caffeine inhibits the checkpoint
kinase ATM. Curr Biol 9(19):1135–1138.
29. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidy-
linositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
J Biol Chem 269(7):5241–5248.
30. Bettayeb K, et al. (2008) CR8, a potent and selective, roscovitine-derived inhibitor of
cyclin-dependent kinases. Oncogene 27(44):5797–5807.
31. Rena G, Bain J, Elliott M, Cohen P (2004) D4476, a cell-permeant inhibitor of CK1,
suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO
Rep 5(1):60–65.
32. Brown EJ, et al. (1994) A mammalian protein targeted by G1-arresting rapamycin-
receptor complex. Nature 369(6483):756–758.
33. Cheng Q, Chen L, Li Z, Lane WS, Chen J (2009) ATM activates p53 by regulating MDM2
oligomerization and E3 processivity. EMBO J 28(24):3857–3867.
34. Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in cancer. Nat Rev
Cancer 14(4):233–247.
35. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING
finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275(12):
8945–8951.
36. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin li-
gase activity of Mdm2 for tumor suppressor p53. EMBO J 18(1):22–27.
37. Shiloh Y, Ziv Y (2013) The ATM protein kinase: Regulating the cellular response to
genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197–210.
38. Zeng YX, Somasundaram K, el-Deiry WS (1997) AP2 inhibits cancer cell growth and
activates p21WAF1/CIP1 expression. Nat Genet 15(1):78–82.
39. Dimri GP, et al. (1995) A biomarker that identifies senescent human cells in culture
and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363–9367.
Malonia et al. PNAS | July 14, 2015 | vol. 112 | no. 28 | 8637
CE
LL
BI
O
LO
G
Y
